Abstract:4-Anilinoquinazoline derivatives function as tyrosine kinase inhibitors (TKIs). Novel TKIs are needed for cancer mutations and drug-resistant cells. We designed and synthesized 4-anilinoquinazoline derivatives with substitutions at quinazoline positions 6, 7 and 4 using a binding model with multi-target receptor tyrosine kinases, and assessed their antitumor activity against five human tumor cell lines (HepG2, A549, MCF-7, DU145, SH-SY5Y). The majority of the compounds inhibited the proliferation of all the cancer cell types, with some compounds displaying selective inhibition. Compounds 21, 25, 27, and 37 displayed IC50 values of 7.588, 8.619, 6.936, and 8.516 μM, respectively, for A549 cells, which were much lower than that of Gefitinib (14.803 μM). Compound 32 displayed an IC50 value of 2.756 μM for DU145 cells. The representative compound 40 had unexceptionable broad-spectrum inhibition for all cancer cell types, and demonstrate inhibition of vascular endothelial growth factor receptor 2 (VEGFR-2), platelet-derived growth factor receptor beta (PDGFR-β), and epidermal growth factor receptor (EGFR) with IC50 values of 46.4, 673.6 and 384.8 nM, respectively, which were similar to those of Sorafenib for VEGFR-2 and PDGFR-β (140.6 and 582.7 nM, respectively). Molecular docking results supported the molecular level assay results. Data for production of reactive oxygen species and assessment of matrix metalloproteinase corroborated the strong anti-proliferative effect of compound 40. The compound also displayed robust antitumor efficacy and relativity lower toxicity in a xenograft model. These attributes were similar to those of Sorafenib. Compound 40 drug warrants further study as a candidate.

Combination of 4-Anilinoquinazoline, Arylurea and Tertiary Amine Moiety to Discover Novel Anticancer Agents.

Development of a Series of Novel 4-Anlinoquinazoline Derivatives Possessing Quinazoline Skeleton: Design, Synthesis, EGFR Kinase Inhibitory Efficacy, and Evaluation of Anticancer Activities in Vitro.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Synthesis of New 4-Anilinoquinazoline Analogues and Evaluation of Their EGFR Inhibitor Activity.

Design, Synthesis, and in Vitro Antitumor Activity Evaluation of Novel 4‐pyrrylamino Quinazoline Derivatives

Novel 4-arylaminoquinazolines bearing N , N -diethyl(aminoethyl)amino moiety with antitumour activity as EGFR wt -TK inhibitor.

Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers

Synthesis and Antitumor Activity of Novel 4-Aminoquinazoline Derivatives Containing Benzothiazole

Design, synthesis and anti-tumor activity evaluation of 4,6,7-substitute quinazoline derivatives

Design, Synthesis, And Antitumor Activity Of Novel Quinazoline Derivatives

Discovery of Potent EGFR Inhibitors with 6-Arylureido-4-anilinoquinazoline Derivatives.

Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.

Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo

Synthesis and in vitro biological evaluation of novel quinazoline derivatives.

Design and Synthesis of Novel Gefitinib Analogues with Improved Anti-Tumor Activity.

Discovery of Novel 4-Anilinoquinazoline Derivatives As Potent Inhibitors of Epidermal Growth Factor Receptor with Antitumor Activity.

Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.

Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors

Synthesis and Biological Evaluation of Selenium-Containing 4-Anilinoquinazoline Derivatives as Novel Antimitotic Agents.

Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors